Clinical Trial
Published on 04 Apr 2024
FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study
in Gastrointestinal Cancers: Colorectal Cancer

- 870 views













